What Is the Significance of New Data on Imsidolimab for GPP? With Neal Bhatia, MD

US Food and Drug Administration (FDA)'s acceptance

 of a Biologics License Application (BLA) for imsidolimab, Vanda Pharmaceuticals' investigational interleukin (IL)-36 receptor inhibitor for 

, could represent a meaningful step forward for a patient population with historically limited treatment options. The therapy is now under formal review as a potential addition to the emerging class of IL-36–targeted agents in dermatology.

Neal Bhatia, MD, a dermatologist at Therapeutics Clinical Research who’s location served as an investigator site for the development of spesolimab (Spevigo; Boehringer Ingelheim), the first IL-36 receptor inhibitor approved for GPP, referred to the development as "novel and well timed." Having another molecule targeting the same pathway, Bhatia highlighted, only adds clinical relevance.

"…[For] many of these patients who suffer in a prison of misdiagnosis or just not having options, this is really some game-changing stuff for them," Bhatia said.

Central to his enthusiasm are the GEMINI-1 and GEMINI-2 trial results, in which a single intravenous dose of imsidolimab led 53% of treated patients to achieve a Generalized Pustular Psoriasis Physician Global Assessment (GPPPGA) score of 0 or 1, suggesting clear or almost clear skin — by week 4, compared with 13% on placebo. Bhatia emphasized that rapid onset is particularly consequential in GPP, where flares can escalate to life-threatening complications including cardiovascular failure and sepsis.

The durability data may be equally compelling. Patients who continued into a roughly 2-year maintenance phase on monthly dosing experienced no disease flares in the active treatment arm, a finding Bhatia described as a significant quality-of-life advance for patients who, even in remission, live in fear of their next episode.

Bhatia also addressed a persistent clinical misconception: the tendency among some dermatologists to reach for IL-17 or IL-23 inhibitors in GPP given their established efficacy in plaque psoriasis. While cytokine pathway overlap exists, he was direct in distinguishing GPP's pathophysiology.

"…GPP is well established in an interleukin-36 milieu, where that cytokine is the main driver," Bhatia expressed. He pointed to the prominent role of neutrophils, reactive oxygen species, and tissue damage unique to IL-36 dysregulation. Targeting that pathway specifically, as both spesolimab and potentially imsidolimab do, is what Bhatia characterized as the key to not just resolving flares, but keeping the disease away.

The quotes contained in this interview summary were edited for clarity.

Smith T. FDA Accepts BLA for Imsidolimab as Generalized Pustular Psoriasis Treatment. HCPLive. February 25, 2026. Accessed March 10, 2026. 

https://www.hcplive.com/view/fda-accepts-bla-imsidolimab-generalized-pustular-psoriasis-treatment

Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis. Vanda Pharmaceuticals, Inc. February 25, 2026. Accessed March 10, 2026. 

https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-fda-acceptance-of-biologics-license-application-filing-for-imsidolimab-for-the-treatment-of-generalized-pustular-psoriasis-302696991.html

Videos

This interview highlights the significance of the potential FDA approval of imsidolimab for patients with generalized pustular psoriasis (GPP).

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Bernard Kadosh, MD, is the medical director of the ventricular assist device and cardiogenic shock programs at NYU Langone Health.

Eiran Gorodeski, MD, MPH, is a professor of medicine and section head of the section of advanced heart failure at Case Western Reserve University School of Medicine, as well as the director of the advanced heart failure and transplant center at University Hospitals.

Multidisciplinary Care and Addressing Pill Burden in HF, With Bernard Kadosh, MD, and Eiran Gorodeski, MD, MPH

 care has become increasingly multidisciplinary, as clinicians from the myriad specialties that affect it come together to address common issues faced by patients, including comorbidities, pill burden, and outcomes.

Several clinical guidelines in recent years have emphasized the importance of multidisciplinary teamwork in the prevention and treatment of HF. In addition to specialists and HF nurses, recommendations encourage primary care physicians to enter the fold as well, making care more accessible in locations which may be limited in their access to specialization.

“We need to demystify heart failure treatment,” Bernard Kadosh, MD, medical director of the ventricular assist device and cardiogenic shock programs at NYU Langone Health, told 

 in an exclusive interview. “You don’t really need an advanced heart failure physician to treat most patients with heart failure. We’re here to lift up the patient when they get to the stage where they may need a little bit more help than what GDMT is able to provide for them. Most of the workforce that will be touching a heart failure patient will probably be internists, primary care physicians, and general cardiologists. It’s incumbent upon us as specialists to make care easier and more accessible.”

Multidisciplinary care can also allow easier access to HF specialists, as primary care providers and other non-specialty clinicians and nurses can conduct non-pharmacological treatment methods. Additionally, multidisciplinary teams can be adapted to several different service models, allowing clinics to address patient concerns at any level.

Increasingly high on the list of concerns in HF treatment is pill burden. In recent years, the manifold prescription medications for various treatments, coupled with a rising distrust in the medical industry at large, have fueled the burden of taking multiple HF drugs among patients.

Recent studies have highlighted the degree to which pill burden affects patients with HF, determining significant variance depending on clinical and psychosocial factors. Additionally, the study discovered that higher burden of treatment increases the risk of adverse health outcomes as a result of lower adherence.

Pill burden is often attributed to the sheer number of crucial HF therapies, including the 4 main pillars of ARNI, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors. In combination, these drugs provide optimal prevention and maintenance of HF – however, all 4 pills are often not taken in conjunction. This naturally increases a patient’s risk of hospitalization, complications, and eventually mortality.

“Patients are willing to take all types of supplements and vitamins, but when you tell them they’ll need to be on 4 medications for heart failure, their eyes are wide open and they’re shocked,” Eiran Gorodeski, MD, MPH, professor of medicine and section head of the section of advanced heart failure at Case Western Reserve University School of Medicine, as well as director of the advanced heart failure and transplant center at University Hospitals, told 

. “First of all, we need to acknowledge the pill burden – to ignore the pill burden will fuel distrust. And then, I think the next step is to explain why those therapies are lifesaving. They reduce the risk of getting hospitalized, they may help the structure of the heart improve, and they improve survival.”

Editors’ Note: Kadosh and Gorodeski report no relevant disclosures.

McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. 

Smith JL, Killian JM, Shippee N, et al. Burden of treatment in patients with heart failure. Journal of the American Heart Association. 2025;14(10). 

Kadosh and Gorodeski discuss the value of including non-specialists in HF care and the challenges of prescribing 4 pills in a time of increasing medical distrust.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

from Charité-Universitätsmedizin Berlin.

BW-20805 Reduces HAE Attacks in Phase 2 Trial, With Markus Magerl, MD

2026 American Academy of Allergy, Asthma & Immunology (AAAAI) 

annual meeting in Philadelphia suggest that BW-20805, an investigational therapy designed to suppress plasma prekallikrein production through a targeted RNA interference approach, may offer long-acting prophylaxis for patients with 

. Phase 2 data show BW-20805 achieved high rates of attack-free outcomes at dosing intervals up to 6 months; the highest dose (600 mg) eliminated HAE attacks.

“This is very amazing data, and it's comparable or even superior to existing therapies,” investigator Markus Magerl, MD, from Charité-Universitätsmedizin Berlin, told 

BW-20805 consists of a small interfering RNA conjugated with N-acetylgalactosamine, enabling targeted delivery to hepatocytes via the asialoglycoprotein receptor. Once inside liver cells, the molecule inhibits messenger RNA responsible for producing prekallikrein, the inactive precursor of plasma kallikrein.

The ongoing open-label, international, multicenter phase 2 trial enrolled adults with HAE type 1 or type 2 and evaluated 3 dosing regimens of the investigational therapy: 600 mg every 24 weeks, 300 mg every 24 weeks, and 300 mg every 12 weeks. At the time of the interim analysis, 14 participants had been dosed, and 10 had post-dose efficacy data beyond day 29. Among those patients, 80% remained completely attack-free during the observation period.

Across dosing groups, the therapy demonstrated substantial reductions in attack frequency. The highest dose cohort experienced a 100% reduction in time-normalized HAE attack rate, while reductions of 89% and 87% were observed in the 300-mg every-24-week and every-12-week groups, respectively.

Within the first month after administration, prekallikrein levels declined by approximately 90% to 97%, depending on the dosing regimen. These reductions remained stable throughout follow-up in participants who continued in the study.

“The drug BW-20805 is doing what we expect to do, reducing the plasma kallikrein activity and reducing it by more than 90% in a very stable way,” Magerl said.

“This shows that the drug is doing exactly what it is designed to do,” Magerl said. “It reduces plasma kallikrein activity in a very stable way.”

The therapy also demonstrated a favorable safety profile in early analyses. Most reported adverse events were mild and transient, primarily consisting of injection-site reactions. The interim analysis observed no treatment-related serious adverse events.

If these findings are confirmed in larger studies, BW-20805 could offer a significant shift in treatment convenience for patients with HAE. Unlike other prophylactic therapies, which often require monthly injections, BW-20805 has an extended dosing interval of every 3 to 6 months.

Despite the encouraging results, Magerl cautioned that the current findings come from a relatively small phase 2 cohort. Additional data will be needed to confirm the durability of efficacy and further characterize long-term safety. Future analyses will focus on longer follow-up periods, potential delayed adverse events, and whether pharmacokinetic data support even longer dosing intervals.

“The data from the phase 2 study is very promising,” Magerl said. “I'm looking forward to [seeing] this data…when the [phase 2] study has been finished and especially the phase 3 data.”

Zhi Y, Zhao X, Zhu R, et al. Significant HAE Attack Reduction with BW-20805, a Long-Acting Prophylactic Injection- An Ongoing Phase 2 Study in Adult with Hereditary Angioedema. Journal of Allergy and Clinical Immunology. 2026;157(2):AB426. 

doi:https://doi.org/10.1016/j.jaci.2025.12.948

At AAAAI 2026, Magerl discusses phase 2 data showing BW-20805 reduced hereditary angioedema attacks by up to 100% with dosing intervals of up to 6 months.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Mohan Satish, MD, is a cardiology fellow at NYP-Weill Cornell.

AMI Mortality Increasing Among Young Adults With Nontraditional Risk Factors, With Mohan Satish, MD

In-hospital mortality has been drastically increasing among young adults with first 

 between 2011 and 2022, particularly among young women, and is associated with more nontraditional risk factors than traditional.

Although mortality from AMI in the US has declined overall in the 2010s, this has largely been driven by older adults and men. Additionally, the prevalence of several modifiable, traditional risk factors is increasing among young adults hospitalized with AMI, with significant sex differences. Many investigators have determined that these parallel trends demand further examination of sex differences and nontraditional risk factors among young adults.

“Our current risk paradigms for understanding somebody’s risk in 10 years and 30 years are very much grounded upon somebody’s traditional risk,” Mohan Satish, MD, a cardiology fellow at NYP-Weill Cornell and lead author of this study, told 

 in an exclusive interview. “What is your blood pressure? What is your cholesterol? We talk about knowing somebody’s numbers, and not so much these non-traditional risk elements. It’s going to take a 2-pronged effort, both from the physician and the patient, to understand these non-traditional risk elements that we’re dealing with and how we can incorporate them to understand somebody’s real risk.”

Satish and colleagues sourced data from the National Inpatient Sample (NIS), examining hospitalizations for first AMI. Patients were included if they were between 18 and 54 years old, excluding those ≥55 years to maintain consistency with existing definitions of “young adults.” Additionally, all hospitalizations with missing data or 0-day length of stay from primary analyses were excluded.

Patient demographics, including age, biological sex, race, ethnicity, and quartile of median household income, were extracted – the lowest household income quartile was included as a nontraditional risk factor. Traditional risk factors included 

, while nontraditional factors included metabolic syndrome, 

, family history of ischemic heart disease, obstructive sleep apnea, hypothyroidism, and others.

The primary outcome for this study was all-cause in-hospital mortality. The team assessed annual in-hospital mortality trends and the incidence of in-hospital complications, including cardiogenic shock, cardiac tamponade, acute stroke, cardiac arrest, major bleed, and others. In parallel, receipt of coronary angiography or coronary revascularization, as well as the receipt of mechanical circulatory support during the index first AMI hospitalization, were analyzed.

From 2011 to 2022, roughly 945,977 hospitalizations in the US had a principal discharge diagnosis of first AMI in young adults, of which 356,115 were STEMI (37.6%), and 589,862 were NSTEMI (62.4%). A higher proportion of STEMI hospitalizations were men compared with women (77.2%), and the lowest income quartile was the most common nontraditional risk factor in STEMI, with a significantly higher prevalence in women (34.9% vs 28.7%; 

 <.001). First NSTEMI hospitalizations were also higher in men (66.2%), and the lowest income quartile was again the most prevalent nontraditional factor in hospitalizations, with a higher prevalence among women (38.1% vs 32.3%; 

From 2011 to 2022, Satish and colleagues saw a substantial increase in unadjusted in-hospital mortality for first STEMI (2.1% to 3.3%, 1.2% absolute increase; 

 for trend <.001). However, it was unchanged for first NSTEMI (0.2% absolute decrease, 

 for trend = .7). Overall, women had a higher in-hospital mortality rate compared with young men in both STEMI (3.1% vs 2.6%; 

 = .03) and saw similar in-hospital complications. However, women also saw significantly lower receipt of cardiovascular procedures.

Ultimately, although in-hospital mortality for both AMI subtypes substantially increased across all subtypes among young adults between 2011 and 2022, mortality for both STEMI and NSTEMI was higher in young women and was associated with nontraditional risk factors. Satish and colleagues determined that further investigation into increasing first STEMI mortality is needed, particularly into sex-based disparities and the prevalence of nontraditional risk factors.

“There are attempts to start to understand risk from a sex-based standpoint,” Satish said. “When somebody hits the hospital, we’re trying to refine our risk models in a sex-based way. There’s been good predictor performance – the idea now is, how do we actually implement that? How do we make providers accountable for using these risk tools? We’re starting to potentially try to implement that.”

Editors’ Note: Satish reports no relevant disclosures.

American Heart Association. Heart attack deaths rose between 2011 and 2022 among adults younger than age 55. 

. February 26, 2026. Accessed March 10, 2026. 

https://www.eurekalert.org/news-releases/1117257

Satish M, Walters RW, Wenzl FA, Safford M, Kini V. Sex differences in outcomes of young adults hospitalized with first myocardial infarction from 2011 to 2022. Journal of the American Heart Association. 2026;15(5). 

Satish discusses his recent study highlighting significant increases in first AMI in-hospital mortality among young adults, particularly in women.

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

New long-term data suggest once-daily roflumilast cream .05% (ZORYVE) can allow for sustained symptom control and a favorable safety profile among children aged 2 - 5 years with 

These data were announced by Arcutis Biotherapeutics, Inc., resulting from the phase 3 open-label extension INTEGUMENT-OLE trial looking at the use of once-daily roflumilast cream .05%, a topical phosphodiesterase-4 inhibitor, in young children living with atopic dermatitis. Atopic dermatitis, the most prevalent form of eczema, is estimated to impact roughly 9.6 million children across the US.

“In my clinical practice, young children with atopic dermatitis struggle with the itchy rash that can cover large portions of their bodies,” Lawrence F. Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children’s Hospital-San Diego and lead author of this publication, said in a statement.

This recent extension study built upon earlier data resulting from the 4-week phase 3 INTEGUMENT‑PED trial, which initially established the safety and efficacy of roflumilast cream .05% in children between 2 and 5 years of age. Data from the INTEGUMENT-OLE study supported the 

US Food and Drug Administration (FDA) approval

 of roflumilast cream .05% in October 2025 for this age cohort.

Over as long as 56 weeks of use, the treatment demonstrated a favorable safety profile and was generally shown to be well-tolerated. Those evaluating the drug had also reported that clinical benefits persisted throughout the study and continued to improve over time.

In the latest open-label safety extension, children were recruited had previously participated in INTEGUMENT-PED and had been given either roflumilast cream .05% or a vehicle cream during that earlier 4-week analysis.

 During the extension phase, there were 562 participants given roflumilast cream .05% once each day as monotherapy for up to 52 weeks to all areas affected by atopic dermatitis except the scalp. Those involved who attained completely clear skin, defined as a Validated Investigator Global Assessment for atopic dermatitis (vIGA-AD) score of 0 at or after Week 4, were transitioned to a proactive twice-weekly maintenance regimen.

Reported efficacy outcomes included results from both individuals who remained on once-daily roflumilast cream and those who moved to the twice-weekly schedule.

 In their assessment of safety, Eichenfield and coauthors found treatment-emergent adverse events (TEAEs) appeared in 49.8% of subjects. Most were classified as mild (24.7%) or moderate (22.2%). The AEs found to have been reported most frequently included upper respiratory tract infection (8.7%), pyrexia (5.0%), and nasopharyngitis (5.0%). Gastrointestinal adverse events occurred in 4.4% of participant.

Serious AEs were documented in 3.2%, though Eichenfield et al determined that none were connected to the treatment.

 Overall, 2.5% of the 562 participants saw treatment-related adverse events, and application-site pain was reported by .7% of these children. Assessments of local tolerability by investigators suggested at least 97% of subjects showed no signs of irritation throughout the study period. In their evaluation of caregiver-reported outcomes, the data suggested minimal discomfort, with burning or stinging sensations rarely seen.

Severe symptoms took place in no more than 1.8% of those treated at any assessment point and were noted among just .3% of children by the 56-week mark. During the analysis, 55 participants reached their sixth birthday and therefore received at least a single application of roflumilast cream .15%. Safety data within this subgroup aligned with those observed in the broader study population.

Secondary endpoints identified in the analysis demonstrated sustained and gradually improving treatment responses.

 Among those who completed the full 56 weeks of treatment, 63.1% attained a vIGA-AD score of clear or almost clear (0 or 1) by the 56-week mark. The investigative team also found 71.9% of children who continued roflumilast therapy and 76.0% of those who switched from vehicle cream to roflumilast attained at least a 75% improvement in the Eczema Area and Severity Index (EASI-75) by the study’s conclusion.

Pruritus improvements were assessed via caregiver reports using the Worst Itch Numeric Rating Scale (WI-NRS).

 By the conclusion of the trial, the team found 57.9% of children who remained on roflumilast and 66.3% of those who transitioned from vehicle treatment reported an improvement of at least 4 points on the scale. Those who saw complete skin clearance following Week 4 transitioned to a twice-weekly proactive treatment schedule. Among the 30.2% of children who entered this maintenance phase, Kaplan-Meier analysis estimated a median duration of disease control of 238 days, defined as maintaining a vIGA-AD rating of clear or almost clear with adequate symptom control while implementing the twice-weekly regimen.

“Providing safe, effective nonsteroidal treatment options for young patients—who can have substantial disease burden but have limited available therapies—remains an important goal in pediatric dermatology,” Eichenfield said in his statement.

 “The publication of these data reinforces [roflumilast] cream 0.05% as a meaningful, long-term treatment option for children living with atopic dermatitis and their families.”

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology. Arcutis Biotherapteutics, Inc. March 10, 2026. 

https://investors.arcutis.com/news-releases/news-release-details/arcutis-announces-publication-positive-long-term-safety-and-0

Smith T. FDA Approves Roflumilast (Zoryve) Cream 0.05% for Atopic Dermatitis in Children Aged 2-5 Years. HCPLive. October 6, 2025. Accessed March 10, 2026. 

https://www.hcplive.com/view/fda-approves-roflumilast-zoryve-cream-0-05-for-atopic-dermatitis-in-children-aged-2-5-years

Articles

Once-daily roflumilast cream 0.05% showed durable efficacy and favorable long-term tolerability in children aged 2–5 years with mild-to-moderate atopic dermatitis over up to 56 weeks. In an open-label extension enrolling prior phase 3 participants, most adverse events were mild-to-moderate, with low rates of treatment-related events and minimal application-site discomfort. Clinical responses were sustained and often improved over time, including vIGA-AD clear/almost clear status, EASI-75, and caregiver-reported pruritus improvement. A proactive twice-weekly maintenance strategy supported prolonged disease control.

These data, resulting from the INTEGUMENT-OLE trial, highlight the efficacy and safety of roflumilast cream (ZORYVE) 0.05% in children aged 2 - 5 years.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

New Long-Term Data Announced on Roflumilast Cream for Atopic Dermatitis in Children

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The approval comes after the FDA requested GSK submit an sNDA for leucovorin for the treatment of CFD-FOLR1.

FDA News

Neurology

Neurology condition center page is a comprehensive resource for clinical news and insights on nervous system disorders. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for Alzheimer's disease, brain injury, PTSD, and more.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

FDA Approves Leucovorin Calcium (Wellcovorin) Tablets as First Cerebral Folate Deficiency Treatment

Nicole Negbenebor, MD, is a clinical assistant professor of dermatology and the director of the Skin of Color Clinic for the University of Iowa, as well as a Skin of Color Society (SOCS) member.

Podcasts

This March episode highlights one SOCS member’s journey in dermatology, covering clinical and research passions as well as lessons learned along the way.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Skin of Color Savvy: The Art and Science of Treating Patients of Color

Hosted by Skin of Color Society and produced by HCPLive, 

 delves into the latest research, clinical insights, and culturally intelligent care practices in dermatology with leading experts. 

Whether it’s groundbreaking research, practice-changing insights, or highlights from the SOCS community, this twice-monthly program provides dermatologists and care providers with expert perspectives on treating patients with skin of color.

Skin of Color Savvy: Challenges and Successes in a Dermatologist’s Career, With Nicole Negbenebor, MD

The expert faculty explore how clinicians approach rectal bleeding and surveillance decisions in colorectal cancer screening.

Video Series

Colorectal Cancer Screening and Surveillance Decisions

 In this episode titled, ‘Shifting Epidemiology and Risk Factors in Colorectal Cancer,’ the moderator introduces the evolving landscape of colorectal cancer screening and highlights the growing importance of early detection.

Shifting Epidemiology and Risk Factors in Colorectal Cancer 

Wood discussed the latest long term data from OUtMATCHat AAAAI 2026.

Food Allergy

OUtMATCH: Omalizumab and OIT Similarly Enable Allergenic Food Consumption, With Robert Wood, MD

Brajan Budini is a medical student at the School of Clinical Medicine and Trinity College, University of Cambridge.

Budini discusses his recent study investigating the trajectory of weight regain after GLP-1 cessation, given current high discontinuation rates.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Discontinuing GLP-1 Treatment Associated With Up to 60% Weight Regain, With Brajan Budini

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

February 2026 saw new data and expert interviews from AAAAI 2026.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

6 Pulmonology Headlines You Missed in February 2026

The FDA accepted Mineralys Therapeutics’ NDA for lorundrostat in hypertension, but the selective aldosterone synthase inhibitor fell short in a phase 2 obstructive sleep apnea trial.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Lorundrostat Secures FDA NDA Acceptance for Hypertension, Falls Short in Phase 2 OSA Trial

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Phase 3 RAINIER exhibits positive results for povetacicept in adults with IgA Nephropathy in a 36 week interim analysis.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

RAINIER: Povetacicept Reduces Proteinuria By 52.0%

Shahinian is a Dr. Robert H and Eva M Moyad Research Professor of UrologyCo-Chief of Dow Division of Health Services ResearchProfessor of Internal Medicine, and Professor of Urology at the University of Michigan Medical School. 

Having a primary care provider may be associated with reduced emergency department utilization for patients with ESKD receiving dialysis, according to new research. 

Latest News

What Is the Significance of New Data on Imsidolimab for GPP? With Neal Bhatia, MD

Multidisciplinary Care and Addressing Pill Burden in HF, With Bernard Kadosh, MD, and Eiran Gorodeski, MD, MPH

BW-20805 Reduces HAE Attacks in Phase 2 Trial, With Markus Magerl, MD

AMI Mortality Increasing Among Young Adults With Nontraditional Risk Factors, With Mohan Satish, MD

New Long-Term Data Announced on Roflumilast Cream for Atopic Dermatitis in Children